Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that the Company will present at two upcoming scientific conferences, including the 12th International Congress on Targeted Anticancer Therapies (TAT), where a poster with data from a Phase 1 trial of VS-6063 (defactinib), a potent inhibitor of focal adhesion kinase (FAK), in Japanese patients with advanced solid tumors will be presented.
Help employers find you! Check out all the jobs and post your resume.
